Summary & Overview
HCPCS J0892: Argatroban Injection for ESRD Patients on Dialysis
HCPCS Level II code J0892 identifies a 1 mg injectable preparation of argatroban (accord) specified for use in patients with end-stage renal disease on dialysis. The code matters nationally because it supports billing for a specialized anticoagulant option in dialysis settings where drug selection and dosing are influenced by renal failure. Accurate coding affects coverage determinations, claims processing, and clinical supply management across dialysis providers and payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise discussion of how J0892 is used in clinical dialysis care, typical sites of service, and the practical implications for payer coverage and claims workflows. The publication provides benchmarks and policy context relevant to medication-specific HCPCS coding, addresses common billing modifiers and service-line considerations (noted elsewhere in the full document), and summarizes where data is available or limited.
This overview is intended for billing professionals, dialysis clinical leaders, and policy analysts seeking a national perspective on how a medication-specific HCPCS Level II code for argatroban integrates into dialysis service billing and payer interactions.
Billing Code Overview
HCPCS Level II code J0892 represents an injection of argatroban (accord), not therapeutically equivalent to J0884, 1 mg, specified for use in patients with end-stage renal disease (ESRD) on dialysis. This code describes a parenteral anticoagulant medication product formulation intended for administration during dialysis care.
Service Type: Medication administration (injectable anticoagulant) for dialysis-related anticoagulation.
Typical Site of Service: Dialysis facility or outpatient dialysis clinic
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis presents for routine dialysis session. The patient has a documented history of heparin-induced thrombocytopenia (HIT) or a clinical contraindication to heparin anticoagulation. The dialysis team orders regional anticoagulation with argatroban administered as an intravenous injection for circuit anticoagulation during the dialysis procedure. Nursing verifies informed consent, reviews allergy and medication history, obtains baseline activated clotting time (ACT) or partial thromboplastin time (aPTT) per local protocol, and prepares argatroban dosing keyed to the patient’s weight and hepatic function. The pharmacy dispenses J0892 (injection, argatroban, 1 mg unit) and documents lot number and expiration; the medication is withheld or wasted as indicated by procedural events and documented with modifier JW if applicable. During dialysis, anticoagulation is monitored; dose adjustments are made per protocol. Post-procedure documentation includes the total milligrams administered, dilution and route, any adverse events, and the indication (ESRD on dialysis with HIT or heparin contraindication). Billing is submitted for the administered units of J0892 with appropriate place-of-service and modifier(s) as required by payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|